GLOW (GHK-Cu + BPC-157 + TB-500)

What it is

The blend comes from the US biohacking scene and is now sold worldwide as a premixed vial. Typical is a large share of GHK-Cu and a smaller share each of BPC-157 and TB-500. Two of the three ingredients are known from the healing duo BPC-157 plus TB-500, which circulates in strength training circles against tendon and muscle injuries. With the copper peptide, the goal shifts from sports injury to skin rejuvenation.

It is remarkable who uses GLOW. The healing stacks were gym culture; GLOW is spreading via beauty and longevity channels. These are the same molecules with a new, much more female audience. The scene often combines the blend with basics such as vitamin C, collagen peptides, sun protection or microneedling.

The ingredients

GHK-Cu is the centerpiece. In 1973, the biochemist Loren Pickart discovered in human blood plasma a tiny peptide of 3 amino acids, glycine, histidine and lysine, that binds a copper ion. The level falls with age: at 20 it is about 200 nanograms per milliliter, at 60 it is 80. Copper is a cofactor of important skin enzymes, such as superoxide dismutase, a radical scavenger produced by the body, and the enzyme that cross-links collagen and elastin fibers. GHK acts like a copper taxi that safely brings free and therefore reactive copper to where it is needed.

BPC-157 is a peptide derived from a protective protein in gastric juice. It is said to promote the formation of new blood vessels and activate connective tissue cells. TB-500 is a short fragment of thymosin beta-4, a protein produced by the body that promotes cell migration and is released by platelets at the site of an injury.

The logic of the three-pack

The scene explains GLOW with an image of a construction site. TB-500 sends the construction workers, that is, repair cells, to the site. BPC-157 builds the access roads, new small vessels for supply. GHK-Cu supplies the blueprint for collagen, elastin and orderly repair instead of scar tissue. Skin is considered an ideal target tissue because it constantly renews itself.

For GHK-Cu there is a gene analysis on this. Using data from the Connectivity Map, a collection of gene responses to active substances, Pickart’s group described in 2015 that GHK changes the activity of at least 4,000 human genes, many of them in the direction of repair and less inflammation. The Connectivity Map is based on gene profiles of cancer cell lines, not on human skin, and the analysis comes from the discoverer of the peptide.

What users report

Reported are plumper-looking skin, finer pores, fewer crinkly lines and faster healing of small blemishes, often along with fuller hair and firmer nails. The typical timeline in user reports: first freshness after 2 to 3 weeks, the actual effect after 6 to 8 weeks. This fits the slowness of skin, because collagen is remodeled over weeks.

These are reports without a control group. Anyone who improves sun protection, sleep and skin care at the same time will also see changes, and expectation plays a large role in judging skin. For fuller hair there are only laboratory data: a related copper peptide, AHK-Cu, elongated isolated human hair follicles in the culture dish.

What the studies show

GHK-Cu creams on aged skin

A 2018 review by the discoverer describes several application studies over 12 weeks. A face cream in 71 women with photoaging increased skin density and skin thickness and reduced fine lines and wrinkle depth. An eye cream in 41 women performed better than placebo and a vitamin K cream. In a small pilot study on thigh skin, GHK-Cu improved collagen formation in 70 percent of the women, compared with 50 percent with vitamin C cream and 40 percent with retinoic acid. The two cream studies on the face and eye area have appeared only as conference contributions; the third is a small pilot study.

Systematic review of GHK-Cu (Mokhtar, 2026)

The authors searched PubMed, Embase and Cochrane up to March 2026. Of 20 included studies, 18 were preclinical and 2 were randomized controlled trials. They see a plausible biological basis, but criticize inconsistent methods and too few well-conducted clinical studies. Microneedles and liposomes markedly improved absorption through the skin.

BPC-157 in a systematic review (Vasireddi, 2025)

Of 36 included studies, 35 were preclinical and 1 clinical, a retrospective analysis on knee pain. In animals, muscle, tendon, ligament and bone healed better. The authors found no clinical safety data.

Where the data stop

There is no published study on the combination of the 3 peptides. Whether they are compatible in a mixture, whether the mixture remains stable in the vial and whether the effects add up has not been tested by anyone. The construction-site logic is coherently reasoned, but it is an addition of individual findings from different tissues and animal models.

The individual components also stand on thin ground for this purpose. The human data on GHK-Cu concern creams on the skin, not injections under the skin, and come largely from the circle around the discoverer. A 2025 review even speaks of a surprising lack of clinical studies. For BPC-157 and TB-500 there is no skin study in humans. A review of six scene peptides, including all three GLOW ingredients, found that 67 percent of publications come from animal models and that the few human studies mostly lack robust controls.

Status, approval and legal

None of the three substances is approved as a medicine in Germany or the EU. GLOW is sold as a research blend; the purity and content of the mixture are up to the vendor. GHK-Cu is widespread as a cosmetic ingredient in serums and creams; that is a different legal framework from an injection. The US Food and Drug Administration (FDA) lists BPC-157, TB-500 and injectable GHK-Cu among compounding substances with potential significant safety risks, in the section on withdrawn nominations. According to the FDA list of May 2026, non-injectable GHK-Cu is being reviewed again. On July 23–24, 2026, an FDA expert panel discussed whether BPC-157 and TB-500 should be permitted for compounded medicines in the US. The FDA’s own reviewers advised against it; the panel nonetheless voted in favor by majority (votes 8:6 with 1 abstention in each case). An FDA decision is pending; a formal procedure is unlikely to begin before 2027. In sport the blend is prohibited: BPC-157 is in class S0, thymosin beta-4 and TB-500 in S2.3 of the 2026 WADA list. We do not give dosages for unapproved substances.

Safety

Long-term safety data in humans are lacking for all three ingredients in injectable form. The FDA lists as risks possible immune reactions, impurities and aggregation of the peptides, as well as missing human data. From the scene, mainly burning and redness at the injection site caused by the copper peptide are reported. Because several ingredients promote new blood vessel formation and cell migration, people with active cancer should avoid the blend. There are no data on pregnancy, pre-existing conditions or interactions with medicines. The best-studied form of GHK-Cu remains the cosmetic on the skin, and for the skin as a whole, sun protection and sleep count for more than any vial.

Sources

• Pickart L, Margolina A, Int J Mol Sci 2018
• Pickart L et al., Biomed Res Int 2015
• Mokhtar J et al., Aesthet Surg J 2026 (systematic review of GHK-Cu)
• Mortazavi SM et al., Bioimpacts 2025
• Pyo HK et al., Arch Pharm Res 2007
• Vasireddi N et al., HSS J 2025
• Treadwell T et al., Ann N Y Acad Sci 2012
• Tewari K et al., Am J Sports Med 2026
• FDA – Bulk Drug Substances with Significant Safety Risks (as of April 22, 2026)
• FDA – Bulk Drug Substances Nominated Under Section 503A (as of May 14, 2026)
• McDermott Will & Schulte – report on the meeting of the FDA panel PCAC, July 23–24, 2026
• WADA Prohibited List 2026, official publication in the Austrian Federal Law Gazette III No. 219/2025